Literature DB >> 35220464

Inflammatory myopathies overlapping with systemic sclerosis: a systematic review.

Jucier Gonçalves Júnior1, Naoki Mugii2, Pleiades Tiharu Inaoka3, Percival Degrava Sampaio-Barros1, Samuel Katsuyuki Shinjo4.   

Abstract

We performed a systematic review of the clinical manifestations and complementary exams of patients with myopathies and systemic sclerosis overlap syndrome (MyoSScOS). Systematic review from January 1976 to November 2021 according PRISMA protocol on three electronic databases: PubMed, Web of Science, and Scopus. Studies were analyzed based on the following eligibility criteria: at least one combination of the terms described in the search strategy appears in the title; written in English, Portuguese, or Spanish; and addresses MyoSScOS. Brief communications, reviews, studies that addressed myopathies in children, congress proceedings, monographs, and dissertations were excluded. Thirty-five articles were selected. MyoSScOS seems to be more common in women. It also commonly affects the esophagus and joints with symmetrical and bilateral muscle involvement, Raynaud's phenomenon, and impairment of forced vital capacity. Concerning SSc, the most common subtype was the diffuse form. Cardiovascular and pulmonary complications are an important cause of death. Anti-centromere, anti-PM/Scl, anti-Scl70, anti-RNA polymerase III, anti-Ku, and anti-RNP were more correlated with this entity, and muscle biopsies may present a more aggressive pattern. Electroneuromyography patterns are quite similar to those found in inflammatory myopathies. The absence of studies with robust methodologies and the large number of case reports and series make more robust statistical analyses such as meta-analyses unfeasible. The characterization of MyoSScOS is important for the formulation of therapeutic measures and specific treatments aiming at better quality of life and prognosis. Greater and better theoretical contributions are necessary to better characterize it.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Inflammatory myopathies; Myositis; Systematic review; Systemic sclerosis

Mesh:

Substances:

Year:  2022        PMID: 35220464     DOI: 10.1007/s10067-022-06115-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

Review 1.  [Muscle involvement in Systemic Sclerosis - diagnosis evaluation].

Authors:  Laura Pinto; Walter Castelão; Jaime Cunha Branco
Journal:  Acta Reumatol Port       Date:  2010 Apr-Jun       Impact factor: 1.290

2.  Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients.

Authors:  Andrea Váncsa; Lajos Gergely; Andrea Ponyi; Gabriella Lakos; Júlia Németh; Péter Szodoray; Katalin Dankó
Journal:  Joint Bone Spine       Date:  2010-02-25       Impact factor: 4.929

3.  Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis.

Authors:  Lisbeth Aranbicia Aguila; Michelle Remião Ugolini Lopes; Flavia Zon Pretti; Percival Degrava Sampaio-Barros; Fernando Henrique Carlos de Souza; Eduardo Ferreira Borba; Samuel Katsuyuki Shinjo
Journal:  Clin Rheumatol       Date:  2014-07-04       Impact factor: 2.980

4.  Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation.

Authors:  Claudio Corallo; Maurizio Cutolo; Nila Volpi; Daniela Franci; Margherita Aglianò; Antonio Montella; Chiara Chirico; Stefano Gonnelli; Ranuccio Nuti; Nicola Giordano
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-03       Impact factor: 5.346

5.  2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Ann Rheum Dis       Date:  2013-11       Impact factor: 19.103

6.  Extended myositis-specific and -associated antibodies profile in systemic sclerosis: A cross-sectional study.

Authors:  Amélie Leurs; Sylvain Dubucquoi; François Machuron; Maïté Balden; Florence Renaud; Stéphanie Rogeau; Benjamin Lopez; Marc Lambert; Sandrine Morell-Dubois; Hélène Maillard; Hélène Béhal; Eric Hachulla; David Launay; Vincent Sobanski
Journal:  Joint Bone Spine       Date:  2020-07-09       Impact factor: 4.929

7.  Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology.

Authors:  Elise Siegert; Akinori Uruha; Carsten Dittmayer; Werner Stenzel; Hans-Hilmar Goebel; Corinna Preuße; Vincent Casteleyn; Felix Kleefeld; Rieke Alten; Gerd R Burmester; Udo Schneider; Jakob Höppner; Kathrin Hahn
Journal:  Acta Neuropathol       Date:  2021-04-17       Impact factor: 17.088

8.  2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Authors:  Ingrid E Lundberg; Anna Tjärnlund; Matteo Bottai; Victoria P Werth; Clarissa Pilkington; Marianne de Visser; Lars Alfredsson; Anthony A Amato; Richard J Barohn; Matthew H Liang; Jasvinder A Singh; Rohit Aggarwal; Snjolaug Arnardottir; Hector Chinoy; Robert G Cooper; Katalin Dankó; Mazen M Dimachkie; Brian M Feldman; Ignacio Garcia-De La Torre; Patrick Gordon; Taichi Hayashi; James D Katz; Hitoshi Kohsaka; Peter A Lachenbruch; Bianca A Lang; Yuhui Li; Chester V Oddis; Marzena Olesinska; Ann M Reed; Lidia Rutkowska-Sak; Helga Sanner; Albert Selva-O'Callaghan; Yeong-Wook Song; Jiri Vencovsky; Steven R Ytterberg; Frederick W Miller; Lisa G Rider
Journal:  Ann Rheum Dis       Date:  2017-10-27       Impact factor: 19.103

9.  Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology.

Authors:  Kavish J Bhansing; Martin Lammens; Hanneke K A Knaapen; Piet L C M van Riel; Baziel G M van Engelen; Madelon C Vonk
Journal:  Arthritis Res Ther       Date:  2014-05-13       Impact factor: 5.156

10.  Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies.

Authors:  Océane Landon-Cardinal; Alexandra Baril-Dionne; Sabrina Hoa; Alain Meyer; Valérie Leclair; Josiane Bourré-Tessier; Anne-Marie Mansour; Farah Zarka; Jean-Paul Makhzoum; Jessica Nehme; Eric Rich; Jean-Richard Goulet; Tamara Grodzicky; Martial Koenig; France Joyal; Isabelle Richard; Marie Hudson; Ira Targoff; Minoru Satoh; Marvin J Fritzler; Yves Troyanov; Jean-Luc Senécal
Journal:  RMD Open       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.